Evidence · Randomised trial
Effects of Lactobacillus reuteri DSM 17938 in preterm infants: a double-blinded randomized controlled study.
- Enteral feeding
- Growth
- Infection
- Infection prevention
- Late-onset sepsis
- Medical
- Necrotising enterocolitis
- Nursing
- Nutrition and gastrointestinal
This paper is from 2019, more than five years ago. Newer evidence may have been published since.
Summary
Randomised controlled trial in 114 formula-fed preterm infants (30-37 weeks, 1500-2000 g) comparing daily Lactobacillus reuteri DSM 17938 from first feed until discharge with no probiotic. Outcomes included early feeding tolerance (time to full enteral feeds, reflux episodes), growth, sepsis, localised infection, NEC and adverse effects. The authors report fewer reflux episodes, more frequent defecation, improved growth and shorter hospital stay with the probiotic. The trial was retrospectively registered and the abstract text is partly truncated.
Summary written for NICUlearn. Always read the original.
- Licence:
- Open (Creative Commons)
The full text of this openly licensed paper is available to NICUlearn members, and Neeky can answer questions from it.
Guidelines are shown for education. Follow your unit's own guidance and senior advice.